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Background: Pheochromocytoma (paraganglioma) of the urinary bladder is a rare tumor. Herein we sought to
review the contemporary literature on pheochromocytomas of the urinary bladder in order to further illustrate the
presentation, treatment options and outcomes of patients diagnosed with these tumors.
Methods: A comprehensive review of the current literature was conducted according to the PRISMA guidelines by
accessing the NCBI PubMed database and using the search terms “paraganglioma, pheochromocytoma, bladder.”
This search resulted in the identification of 186 articles published between January 1980 and April 2012 of which 80
articles were ultimately included in our analysis.
Results: Pheochromocytomas usually occurred in young adult Caucasians (mean age, 43.3 years; range,
11–84 years). According to the literature, the most common symptoms and signs of pheochromocytomas of the
urinary bladder were hypertension, headache, and hematuria. Of the 77 cases that commented on catecholamine
production, 65 patients had biochemically functional tumors. Approximately 20% of patients were treated by
transurethral resection alone, 70% by partial cystectomy and 10% by radical cystectomy. The 75 patients with
follow-up information had a mean follow-up of 35 months. At the time of last follow-up, 15 (14.2%) had disease
recurrence, 10 (9.4%) had metastasis, and 65 (61.3%) were alive.
Conclusions: Pheochromocytomas of the urinary bladder tend to be functional and occur mostly in young adult
Caucasians. Patients with localized tumors have an extremely favorable prognosis and may be managed by less
aggressive modalities, whereas patients with metastatic disease have a significant reduction in survival rates despite
aggressive treatment.
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Pheochromocytoma of the urinary bladder is a rare
tumor that originates from chromaffin tissue of the
sympathetic nervous system associated with the urinary
bladder wall. Pheochromocytomas are tumors of the
sympathetic nervous tissue and may be non-functional
or functional, i.e., secrete catecholamine causing parox-
ysmal hypertension, palpitation, and micturition syncope
[1]. Typically these tumors possess the capacity to invade
and thus are deemed malignant, yet lack mitoses and cellu-
lar dissociation that are usually associated with malignant
tumors [2]. Numerous, small series case reports have been* Correspondence: charles.rosser@orlandohealth.com
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reproduction in any medium, provided the orpublished in the English literature since it was first reported
in 1953 by Zimmerman et al. [3]. Herein we sought to
review the contemporary literature on pheochromocytoma
of the urinary bladder in hopes of further clarifying presen-
tation, treatment options and outcomes of patients with
pheochromocytomas of the urinary bladder.Methods
A review of the current literate was conducted by
accessing the NCBI PubMed database (http://www.ncbi.
nlm.nih.gov/pubmed). Filters applied in an advanced
search included: the search terms of “paraganglioma,
pheochromocytoma, bladder”; English language; human
subjects 19 years of age and older; publication dates of
January 1980 to April 2012. Figure 1 illustrates the
work-flow of the comprehensive literature review, whichtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Pubmed advanced search 
- Search terms: paraganglioma, bladder
- Language: English
- Subjects: Humans, 19+ yrs old





Data included on 106 
patients
31: Abstracts unavailable online
2: Entries are not case reports
31: PG not specifically in urinary bladder
16: Entry not a case report
4: PG found with additional malignancy 
1: PG examined post-mortem




25: Article did not include key data about the patient(s) 
9: PG not specifically in urinary bladder 
4: PG found with additional malignancy
2: Report is a recurrence, not initial tumor presentation 
1: Entry is not a case report
Figure 1 Literature search schema.
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This search delivered 186 results from which 153 abstracts
were reviewed. A total of 121 articles were ultimately
reviewed in full. Patient characteristics were divided
into “primary” and “secondary” demographics for ease
of data recording. Reasons for exclusion included missing
any primary demographic (patient age, sex, presenting
symptoms, type of surgery) or more than three secondary
demographics (patient race, catecholamine levels, tumor
size, tumor grade and stage, last follow up). Due to failure
to report primary demographics and/or secondary demo-
graphics, an additional 25 articles eventually were excluded
from final analysis. Thus the final analysis comprised 80
articles that reported on 106 patients. Relevant clinical,
pathologic, laboratory, radiologic and follow-up data from
these 80 articles were collected in a database, which allowed
the reporting of descriptive statistics.
Results
Eighty articles on pheochromocytoma of the urinary
bladder were identified on Pubmed and were incorporated
in our analysis, which included 106 patients [4-82].
The demographics and presenting symptomology are
summarized in Table 1. The mean patient age was
43.3 years (range, 11–84 years). The male-to-female ra-
tio was 1.07 to 1. The most common symptoms werehypertension (54.7%), headache (48.1%), hematuria
(47.2%) and syncope/palpitations (43.4%). Micturition
attacks were reported in 52.8% of patients.
Average tumor size was 3.9 cm (median 3.45, range
1–9.1 cm). Few studies (n = 7) reported exact tumor
stage by the TNM criteria. Of the 106 patients, 65 (61.3%)
were noted to have a functional paraganglioma as
evident by elevated VMA, metanephrine and/or cate-
cholamines. Furthermore, limited articles reported on
CD56, Chromagranin A, and synaptophysin immunohis-
tochemical staining.
The most commonly reported treatment for patients
with paraganglioma of the urinary bladder was partial
cystectomy 73 (68.9%). Other treatment options for
localized/locally advanced paraganglioma of the urinary
bladder include TURBT (21; 19.8%) and radical cystec-
tomy (12; 11.3%). Thirty-one patients included in this
study did not have known follow-up. Mean follow of
the remaining cohort was 34.6 months (median 18;
range 0.75-372 months). Fifteen patients (14.2%)
were noted to develop a recurrence of the tumor,
while 60 patients (56.6%) had no evidence of disease.
Metastatic recurrence was noted in ten patients (9.4%). Ten
patients (9.4%) were deceased at last follow-up. Of these 10
patients who died, four (3.8%) presented with locally ad-
vanced or metastatic disease. Thus, patients who presented







Mean age (years) 43.3
Age range (years) 11-84
Presenting symptom(s)






Micturition disturbances (e.g., urgency, dysuria) 11 (10.4)
Dizziness 10 (9.4)
Abdominal/flank pain 6 (5.7)
Dyspnea/chest pain 5 (4.7)
Malaise 3 (2.8)
Incidental finding 3 (2.8)
Other 11 (10.4)
Catecholamines
↑ VMA, metanephrine, or catecholamines 65 (61.3)
Unknown/not mentioned 29 (27.4)
Tumor size
Mean (cm) 3.9
Median (range) (cm) 3.45 (1.0-9.1)
Unknown/not mentioned 26 (24.5)
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have a significantly improved survival compared to pa-
tients who presented with locally advanced/metastatic
disease.
Discussion
Pheochromocytomas of the urinary bladder are exceedingly
rare tumors accounting for less than 0.05% of all bladder
tumors and less than 1% of all pheochromocytomas. In
the genitourinary tract, the urinary bladder is the most
common site for pheochromocytomas (79.2%), followed
by the urethra (12.7%), pelvis (4.9%), and ureter (3.2%)
[82,83]. Furthermore, approximately 10% of all extra
adrenal pheochromocytomas are malignant [83]. Since this
is such a rare condition, limited, large reports are available
to direct clinical decision making. We extensively reviewed
the English literature on this subject and report the largest
analysis of pheochromocytomas involving the urinarybladder. Our study improves upon previous large reviews
[5,84]. For example, Tsai et al. includes one study dating
back to 1911, and then eleven studies between 1989 and
2000 [5]. Our study includes 80 studies between 1980 and
2012, offering a better view for analyzing contemporary
outcomes. In addition, we have a total of 106 patients
included in our study, the most of any literature review to
date, while Tsai et al. only reported on 53 patients. Lastly,
our review used a multitude of demographics to depict
the disease process of bladder pheochromocytomas,
including presenting symptoms, tumor functionality, tumor
size, treatment modality and outcomes.
Symptoms reported in the current literature range
from the typical micturition attacks of headache and
palpitations to more abstract signs such as paraesthesias
and dyspnea. While select patients may lack more common
presenting symptoms of bladder pheochromocytoma, e.g.,
hypertension, others may develop hematuria and lower
urinary tract symptoms, testifying to the variability in
which this disease can present itself. Furthermore, the
consequences of hypertension itself may muddle the
initial diagnostic picture of these patients. Patients
often seek medical attention only when their hypertension
has become so advanced as to cause syncope, retinopathy,
or intracranial hemorrhage [85]. Physicians must constantly
be wary of an undiagnosed pheochromocytoma in the set-
ting of unexplained hypertension or associated symptoms.
Pheochromocytomas can be treated in a number of ways,
including catecholamine blockade, surgery, chemotherapy,
and radiation therapy. The standard treatment modality
for localized or locally advanced pheochromocytomas is
surgery, while metastatic or recurrent tumora are treated
with palliative therapy [86]. Furthermore, physicians
must be aware of poor prognostic indicators, such as
large tumor size, advanced stage (≥T3), multifocal tu-
mors, DNA ploidy, and CgA expression [84]. The
cyclophosphamide, vincristine, and dacarbazine (the
Averbuch protocol) has been shown to be effective against
advanced malignant pheochromocytoma [87]. Radiation
therapy with 131I-MIBG radiation therapy has been used
with good efficacy for the treatment of MIBG-avid metasta-
ses [88]. Approximately 70% of patients included in our lit-
erature review underwent partial cystectomy as a means
of primary treatment. Including those who underwent
radical cystectomy, over 80% of patients were initially
treated with aggressive surgical excision. Of the 75 pa-
tients with reported follow up, 15 (20%) experienced re-
currence or metastasis at the time of last follow-up,
illustrating that good symptomatic control and lower mor-
bidity can be achieved with the surgical resection. It is im-
portant to note, however, that 4 of these 75 patients (5.3%)
did have recurrence or metastases that ultimately caused
their death. In the face of metastatic pheochromocytoma,
surgical treatment is rarely curative. It may, however,
Beilan et al. BMC Urology 2013, 13:22 Page 4 of 6
http://www.biomedcentral.com/1471-2490/13/22adequately prolong survival by reducing comorbid condi-
tions (i.e. hypertension) and reducing tumor burden, but
adjunct therapies are usually indicated [89]. Thus patients
should be counseled according to their individual presen-
tation and disease status.
Furthermore, with a lack of high quality data and the
lack of organizational guidelines (e.g., EAU, NCCN and
AUA) on post-operative follow-up, we recommend no
follow-up studies in patients with benign, localized dis-
ease. In patients with functional tumors, regardless of
stage, VMA, metanephrine and catecholamines levels
should be monitored within one month post-surgery,
then every six months for two years. Furthermore if re-
gional or metastatic is documented then axial imaging
of the abdomen/pelvis should be performed every three
months for one year, then every six months for one year,
then yearly for three years.
The main limitations of our study relate to its retro-
spective nature and the large disparity among reporting
styles of various institutions. For example, the vast
majority of case reports included in this study report on
patients presenting with localized or regional disease
rather than metastatic disease. This may represent a bias
toward reporting on patient’s who’s therapeutic timeline
can better be used as an educational platform. The lack
of uniformity on how oncologic cases are presented
makes it difficult to characterize the true disease course
of bladder pheochromocytoma. Information such as
patient race, diagnostic findings, and laboratory values
should be included whenever possible to better illustrate
the pathophysiologic process. Currently, there is no
standard staging system for pheochromocytomas. The
National Cancer Institute at the National Institute of
Health recommends dividing patients into three categories:
localized, regional, and metastatic disease. In terms of
grade and cellular classification of these tumors, the
NCI identifies four pathologic features associated with
malignancy: large tumor size, increased number of
mitosis, DNA aneuploidy, and extensive tumor necrosis
[86]. The complete tumor stage and grade are vital
additions to any oncologic case report. Describing
these characteristics and developing standard reporting
criteria will enable future investigations to better collect
and analyze information from case reports.
Conclusions
In summary, pheochromocytomas of the urinary bladder
tend to be functional and occur mostly in young adult
Caucasians. Initial presentation is extremely varied in
these cancers, necessitating a low threshold of suspicion
in the face of hypertension or hematuria. Patients with
localized tumors have a favorable prognosis and may be
managed by less radical modalities, whereas patients
with metastatic disease have a significantly reducedsurvival rate. Moving forward, it would be helpful to
standardize the reporting guidelines of pheochromocy-
tomas cases to better understand the natural process
and outcomes.
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